



I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on: 3/28/01

Date

By: Winsome A. Dunn

Winsome A. Dunn

RECEIVED

APR 13 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Ning Zhang, et al.

SERIAL NO.: 09/465,978

FILED: December 16, 1999

FOR: **Methods and Compositions for Screening for Angiogenesis Modulating Compounds**

EXAMINER: R. Shukla

ART UNIT: 1632

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES AND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231
Box: Sequence

Sir:

In response to the Office action mailed February 28, 2001, in the above-identified application, please amend the application as follows.

IN THE SPECIFICATION:

Please replace the originally-filed Sequence Listing with the enclosed substitute pages containing the Sequence Listing.

REMARKS

In the Office Action dated, February 28, 2001, The Examiner has noted that the subject application fails to comply with the requirements of 37 CFR 1.821-1.825, for failing to include the Sequence Listing in computer-readable form (CRF). The Examiner has requested (i) an initial or substitute CRF copy of the Sequence Listing, (ii) an initial or substitute paper copy of the Sequence Listing together with an amendment directing its entry into the specification, and (iii) a statement that the content of the paper and computer readable copies are the same, and that they do not introduce new matter.